4298ba3efbc3db70235bb8f7a7e2f2ef Diaobemet_a2017v19p1408iENG.pdf 10a118d5815368b236f4ce483c0c6f69ddddb44f Diaobemet_a2017v19p1408iENG.pdf c56931890ed809acabea10feaaca9ac66306aa46f35dcbd54078ae0a3c9737c0 Diaobemet_a2017v19p1408iENG.pdf Title: Consistent findings in glycaemic control, body weight and hypoglycaemia with iGlarLixi (insulin glargine/lixisenatide titratable fixed-ratio combination) versus insulin glargine across baseline HbA1c, BMI and diabetes duration categories in the LixiLan-L trial: Creator: Arbortext Advanced Print Publisher 9.1.520/W Unicode Producer: Acrobat Distiller 7.0 (Windows) CreationDate: Thu Sep 7 09:35:37 2017 CEST ModDate: Thu Sep 7 09:36:24 2017 CEST Tagged: no UserProperties: no Suspects: no Form: none JavaScript: no Pages: 8 Encrypted: no Page size: 595.276 x 782.362 pts Page rot: 0 File size: 1188719 bytes Optimized: yes PDF version: 1.7 name type encoding emb sub uni object ID ------------------------------------ ----------------- ---------------- --- --- --- --------- GMKBCC+AdvTTfac587ca.B Type 1C WinAnsi yes yes no 163 0 GMKBDD+AdvTT6071803a.B Type 1C WinAnsi yes yes no 156 0 GMKBED+AdvTTa9c1b374 Type 1C WinAnsi yes yes no 157 0 GMKBEE+AdvTTeb5f0e55.I Type 1C WinAnsi yes yes no 162 0 GMKBFF+AdvTTa9c1b374+22 Type 1C Custom yes yes yes 158 0 GMKBHF+AdvTTa9c1b374+20 Type 1C Custom yes yes yes 159 0 GMKBIG+AdvP4C4E74 Type 1C Custom yes yes no 43 0 GMKBIH+AdvOT8608a8d1 Type 1C WinAnsi yes yes no 44 0 GMKBII+AdvOT8608a8d1+03 Type 1C Custom yes yes yes 45 0 GMKCAG+AdvTT6071803a.B+22 Type 1C Custom yes yes yes 46 0 GMKCND+STIXGeneral-Bold Type 1C Custom yes yes yes 49 0 GMKCNE+HelveticaLTStd-Roman Type 1C WinAnsi yes yes no 47 0 GMKCNC+Calibri-Bold TrueType WinAnsi yes yes no 48 0 Jhove (Rel. 1.6, 2011-01-04) Date: 2019-02-14 18:17:59 CET RepresentationInformation: Diaobemet_a2017v19p1408iENG.pdf ReportingModule: PDF-hul, Rel. 1.8 (2009-05-22) LastModified: 2018-10-10 19:10:24 CEST Size: 1188719 Format: PDF Version: 1.7 Status: Well-Formed and valid SignatureMatches: PDF-hul MIMEtype: application/pdf Profile: Linearized PDF PDFMetadata: Objects: 181 FreeObjects: 1 IncrementalUpdates: 1 DocumentCatalog: PageLayout: SinglePage PageMode: UseNone Outlines: Item: Title: Consistent findings in glycaemic control, body weight and hypoglycaemia with iGlarLixi (insulin glargine/lixisenatide titr... Destination: edu.harvard.hul.ois.jhove.module.pdf.PdfSimpleObject@16f65612 Children: Item: Title: 1 INTRODUCTION Destination: edu.harvard.hul.ois.jhove.module.pdf.PdfSimpleObject@311d617d Item: Title: 2 MATERIALS AND METHODS Destination: edu.harvard.hul.ois.jhove.module.pdf.PdfSimpleObject@7c53a9eb Children: Item: Title: 2.1 Trial design Destination: edu.harvard.hul.ois.jhove.module.pdf.PdfSimpleObject@ed17bee Item: Title: 2.2 Trial population Destination: edu.harvard.hul.ois.jhove.module.pdf.PdfSimpleObject@2a33fae0 Item: Title: 2.3 Randomization and interventions Destination: edu.harvard.hul.ois.jhove.module.pdf.PdfSimpleObject@707f7052 Item: Title: 2.4 Subpopulation analysis Destination: edu.harvard.hul.ois.jhove.module.pdf.PdfSimpleObject@11028347 Item: Title: 2.5 Statistical methods Destination: edu.harvard.hul.ois.jhove.module.pdf.PdfSimpleObject@14899482 Item: Title: 3 RESULTS Destination: edu.harvard.hul.ois.jhove.module.pdf.PdfSimpleObject@21588809 Children: Item: Title: 3.1 Main study analysis Destination: edu.harvard.hul.ois.jhove.module.pdf.PdfSimpleObject@2aae9190 Item: Title: 3.2 Glycaemic control according to baseline HbA1c, duration of T2DM and BMI Destination: edu.harvard.hul.ois.jhove.module.pdf.PdfSimpleObject@2f333739 Item: Title: 3.3 Body weight change by subpopulation Destination: edu.harvard.hul.ois.jhove.module.pdf.PdfSimpleObject@77468bd9 Item: Title: 3.4 Hypoglycaemia by subpopulation Destination: edu.harvard.hul.ois.jhove.module.pdf.PdfSimpleObject@12bb4df8 Item: Title: 4 DISCUSSION Destination: edu.harvard.hul.ois.jhove.module.pdf.PdfSimpleObject@4cc77c2e Item: Title: 4 ACKNOWLEDGEMENTS Destination: edu.harvard.hul.ois.jhove.module.pdf.PdfSimpleObject@7a7b0070 Children: Item: Title: 4 Conflict of interest Destination: edu.harvard.hul.ois.jhove.module.pdf.PdfSimpleObject@39a054a5 Item: Title: Author contributions Destination: edu.harvard.hul.ois.jhove.module.pdf.PdfSimpleObject@71bc1ae4 Item: Title: REFERENCES Destination: edu.harvard.hul.ois.jhove.module.pdf.PdfSimpleObject@6ed3ef1 Info: Title: Consistent findings in glycaemic control, body weight and hypoglycaemia with iGlarLixi (insulin glargine/lixisenatide titratable fixed-ratio combination) versus insulin glargine across baseline HbA1c, BMI and diabetes duration categories in the LixiLan-L trial: Creator: Arbortext Advanced Print Publisher 9.1.520/W Unicode Producer: Acrobat Distiller 7.0 (Windows) CreationDate: Thu Sep 07 10:05:37 CEST 2017 ModDate: Thu Sep 07 10:06:24 CEST 2017 ID: 0x253c8e852a61d9be3cba8bb10e469bb5, 0x13348c9e6fad3ee0d4d74e6b4e364fff Filters: FilterPipeline: FlateDecode Fonts: Type1: Font: BaseFont: GMKCND+STIXGeneral-Bold FontSubset: true FirstChar: 2 LastChar: 2 FontDescriptor: FontName: GMKCND+STIXGeneral-Bold Flags: Symbolic FontBBox: -1030, -455, 2000, 1055 FontFile3: true EncodingDictionary: Differences: true ToUnicode: true Font: BaseFont: GMKBEE+AdvTTeb5f0e55.I FontSubset: true FirstChar: 44 LastChar: 121 FontDescriptor: FontName: GMKBEE+AdvTTeb5f0e55.I Flags: Nonsymbolic FontBBox: -83, -177, 989, 927 FontFile3: true Encoding: WinAnsiEncoding Font: BaseFont: GMKBCC+AdvTTfac587ca.B FontSubset: true FirstChar: 49 LastChar: 85 FontDescriptor: FontName: GMKBCC+AdvTTfac587ca.B Flags: Nonsymbolic FontBBox: -72, -177, 1062, 958 FontFile3: true Encoding: WinAnsiEncoding Font: BaseFont: GMKBIG+AdvP4C4E74 FontSubset: true FirstChar: 1 LastChar: 1 FontDescriptor: FontName: GMKBIG+AdvP4C4E74 Flags: Symbolic FontBBox: -20, -958, 1114, 770 FontFile3: true EncodingDictionary: Differences: true Font: BaseFont: GMKBDD+AdvTT6071803a.B FontSubset: true FirstChar: 37 LastChar: 124 FontDescriptor: FontName: GMKBDD+AdvTT6071803a.B Flags: Nonsymbolic FontBBox: -52, -177, 1041, 947 FontFile3: true Encoding: WinAnsiEncoding Font: BaseFont: GMKBIH+AdvOT8608a8d1 FontSubset: true FirstChar: 42 LastChar: 215 FontDescriptor: FontName: GMKBIH+AdvOT8608a8d1 Flags: Nonsymbolic FontBBox: -62, -208, 927, 958 FontFile3: true Encoding: WinAnsiEncoding Font: BaseFont: GMKBED+AdvTTa9c1b374 FontSubset: true FirstChar: 35 LastChar: 248 FontDescriptor: FontName: GMKBED+AdvTTa9c1b374 Flags: Nonsymbolic FontBBox: -41, -177, 1010, 927 FontFile3: true Encoding: WinAnsiEncoding Font: BaseFont: GMKBII+AdvOT8608a8d1+03 FontSubset: true FirstChar: 1 LastChar: 3 FontDescriptor: FontName: GMKBII+AdvOT8608a8d1+03 Flags: Symbolic FontBBox: -479, -364, 854, 927 FontFile3: true EncodingDictionary: Differences: true ToUnicode: true Font: BaseFont: GMKBFF+AdvTTa9c1b374+22 FontSubset: true FirstChar: 1 LastChar: 138 FontDescriptor: FontName: GMKBFF+AdvTTa9c1b374+22 Flags: Symbolic FontBBox: 0, -166, 677, 854 FontFile3: true EncodingDictionary: Differences: true ToUnicode: true Font: BaseFont: GMKCAG+AdvTT6071803a.B+22 FontSubset: true FirstChar: 1 LastChar: 1 FontDescriptor: FontName: GMKCAG+AdvTT6071803a.B+22 Flags: Symbolic FontBBox: -10, -166, 677, 843 FontFile3: true EncodingDictionary: Differences: true ToUnicode: true Font: BaseFont: GMKBHF+AdvTTa9c1b374+20 FontSubset: true FirstChar: 1 LastChar: 144 FontDescriptor: FontName: GMKBHF+AdvTTa9c1b374+20 Flags: Symbolic FontBBox: -239, -218, 1166, 937 FontFile3: true EncodingDictionary: Differences: true ToUnicode: true Font: BaseFont: GMKCNE+HelveticaLTStd-Roman FontSubset: true FirstChar: 65 LastChar: 67 FontDescriptor: FontName: GMKCNE+HelveticaLTStd-Roman Flags: Nonsymbolic FontBBox: -166, -225, 1000, 931 FontFile3: true Encoding: WinAnsiEncoding TrueType: Font: BaseFont: GMKCNC+Calibri-Bold FontSubset: true FirstChar: 32 LastChar: 111 FontDescriptor: FontName: GMKCNC+Calibri-Bold Flags: Nonsymbolic FontBBox: -519, -306, 1240, 971 FontFile2: true Encoding: WinAnsiEncoding XMP: Consistent findings in glycaemic control, body weight and hypoglycaemia with iGlarLixi (insulin glargine/lixisenatide titratable fixed-ratio combination) versus insulin glargine across baseline HbA1c, BMI and diabetes duration categories in the LixiLan-L trial: Pages: Page: Label: 1408 Sequence: 1 Annotations: Annotation: Subtype: Link Rect: 151, 533, 160, 541 Annotation: Subtype: Link Rect: 340, 161, 395, 169 Annotation: Subtype: Link Rect: 184, 52, 308, 58 Annotation: Subtype: Link Rect: 76, 22, 169, 28 Page: Label: 1409 Sequence: 2 Page: Label: 1410 Sequence: 3 Page: Label: 1411 Sequence: 4 Page: Label: 1412 Sequence: 5 Page: Label: 1413 Sequence: 6 Page: Label: 1414 Sequence: 7 Page: Label: 1415 Sequence: 8 Annotations: Annotation: Subtype: Link Rect: 58, 620, 186, 628 Checksum: f839b1a1 Type: CRC32 Checksum: 4298ba3efbc3db70235bb8f7a7e2f2ef Type: MD5 Checksum: 10a118d5815368b236f4ce483c0c6f69ddddb44f Type: SHA-1